{
    "Trade/Device Name(s)": [
        "cobas\u00ae BKV"
    ],
    "Submitter Information": "Roche Molecular Systems, Inc.",
    "510(k) Number": "K203220",
    "Predicate Device Reference 510(k) Number(s)": [
        "K202215"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLX"
    ],
    "Summary Letter Date": "October 30, 2020",
    "Summary Letter Received Date": "November 2, 2020",
    "Submission Date": "October 30, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.3183"
    ],
    "Regulation Name(s)": [
        "Quantitative Viral Nucleic Acid Test for Transplant Patient Management"
    ],
    "Analyte Class(es)": [
        "transplant",
        "virology"
    ],
    "Analyte(s)": [
        "BK virus (BKV) DNA"
    ],
    "Specimen Type(s)": [
        "EDTA plasma",
        "Urine"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "cobas\u00ae PCR Media tube"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas\u00ae 6800 System",
        "cobas\u00ae 8800 System"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time PCR",
        "Nucleic acid amplification",
        "Automated sample preparation"
    ],
    "Methodologies": [
        "PCR amplification",
        "Dual-target detection",
        "Fluorescence probe detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for Roche cobas BKV assay using real-time PCR on cobas 6800/8800 Systems to quantify BK virus DNA in EDTA plasma and urine for transplant patient management.",
    "Indications for Use Summary": "Intended as an in vitro nucleic acid amplification test for quantitation of BK virus DNA in EDTA plasma and urine (stabilized in cobas PCR media) as an aid in managing BKV in transplant patients; for use on the cobas 6800/8800 Systems.",
    "fda_folder": "Microbiology"
}